You are here

Bioibérica presents the latest scientific evidence on osteoarthritis at the European Congress of Rheumatology (EULAR 2016)

3 Jun 2016
Healthcare

Symposium on Friday, June 10, 2016 at 08:15

The company, with more than 40 years of experience in osteoarthritis and joint health, presents a symposium with top-level specialists about the new scientific evidence available on the treatment of osteoarthritis.
Program:

Overall treatment effect and contextual effect of osteoarthritis treatments: meta-analysis of randomized clinical trials

Weiya Zhang, BM, MPH, PhD (Nottingham, UK)

Drug use and risk of comorbidities in osteoarthritis

Philip Conaghan, MB BS, PhD, FRACP, FRCP (Leeds, UK)

Chondroitin sulphate for hand osteoarthritis: a randomized, placebo-controlled trial in primary care: the FACTUAL study

George Peat, PhD, MCSP (Keele, UK)

MOSAIC:  24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulphate

Jean-Pierre Pelletier, MD (Montreal, Quebec, Canada)

Long-term effects of treatment on the progression of structural changes in knee osteoarthritis: new follow-up data from the Osteoarthritis Initiative cohort

Johanne Martel-Pelletier, PhD (Montreal, Quebec, Canada)

Long term use of analgesics and risk of osteoarthritis progression and knee replacement from the Osteoarthritis Initiative cohort.

Ali Guermazi, MD, PhD (Boston, MA, USA) 

Bioiberica